23.81k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Watchlist | Change today | 1-month return | 1-year return | Total return |
---|---|---|---|---|
The fight against COVID19 | +0.66% | - | - | - |
^GSPC | +1.26% | -1.43% | +23.92% | +5413.75% |
Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
---|---|---|---|---|---|---|---|---|
JNJ | Johnson & Johnson | 149.27 | -0.65 | -0.43% | 4:00 pm GMT-4 | 6.53M | 7.74M | 359.25B |
ABBV | AbbVie Inc. | 163.79 | +2.98 | +1.85% | 4:00 pm GMT-4 | 5.85M | 5.72M | 290.01B |
PFE | Pfizer Inc. | 27.81 | +0.11 | +0.40% | 4:00 pm GMT-4 | 60.57M | 41.42M | 157.48B |
SNY | Sanofi | 49.01 | -0.45 | -0.91% | 4:00 pm GMT-4 | 1.11M | 2.12M | 122.94B |
REGN | Regeneron Pharmaceuticals, Inc. | 957 | +19.39 | +2.07% | 4:00 pm GMT-4 | 547.37k | 469.05k | 105.45B |
GSK | GSK plc | 43.5 | +0.15 | +0.35% | 4:00 pm GMT-4 | 4.05M | 3.42M | 88.70B |
GILD | Gilead Sciences, Inc. | 64.78 | -0.55 | -0.84% | 4:00 pm GMT-4 | 7.82M | 7.41M | 80.78B |
MRNA | Moderna, Inc. | 125 | -0.59 | -0.47% | 4:00 pm GMT-4 | 4.51M | 3.94M | 47.91B |
TAK | Takeda Pharmaceutical Company Limited | 13.37 | +0.10 | +0.75% | 4:00 pm GMT-4 | 1.33M | 1.65M | 42.28B |
BNTX | BioNTech SE | 92.72 | +0.48 | +0.52% | 4:00 pm GMT-4 | 663.33k | 590.52k | 22.34B |
VIR | Vir Biotechnology, Inc. | 10.39 | +1.21 | +13.18% | 4:00 pm GMT-4 | 1.69M | 1.04M | 1.41B |
NVAX | Novavax, Inc. | 4.93 | +0.22 | +4.67% | 4:00 pm GMT-4 | 4.67M | 6.94M | 692.19M |
INO | Inovio Pharmaceuticals, Inc. | 12.1 | +0.09 | +0.75% | 4:00 pm GMT-4 | 295.95k | 469.30k | 313.47M |
A little patience with the drugmaker should pay off.
Can the biotech succeed after a string of failures?
GSK plc (NYSE:GSK) Q1 2024 Earnings Call Transcript May 4, 2024 GSK plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Nick Stone: Hello everyone. Welcome to today’s call and webcast. The presentation was sent to our distribution list by email, and […]